Iris Dorbian

Sofinnova Partners closes medtech acceleration fund

Sofinnova Partners has raised 48 million euros for its new medtech acceleration fund, beating its target of 40 million euros. MD Start III's investors include Bpifrance, Medtronic, LivaNova, the European Investment Fund and Baxter Healthcare Corporation.

Sofinnova Partners closes medtech acceleration fund

Sofinnova Partners has raised 48 million euros for its new medtech acceleration fund, beating its target of 40 million euros. MD Start III's investors include Bpifrance, Medtronic, LivaNova, the European Investment Fund and Baxter Healthcare Corporation.

Arris Composites rakes in $10 mln Series A

Arris Composites, a provider of next-gen composites for mass market applications, has raised $10 million in Series A funding. New Enterprise Associates led the round.

Arris Composites rakes in $10 mln Series A

Arris Composites, a provider of next-gen composites for mass market applications, has raised $10 million in Series A funding. New Enterprise Associates led the round.

Amastan Technologies reels in $11 mln

North Andover, Massachusetts-based Amastan Technologies, a provider of advanced ceramic, metal and composite materials, has secured $11 million in funding. Anzu Partners led the round. Also, Amastan has acquired Pennsylvania-based AL Solutions Inc, a producer of refined titanium materials for the aerospace, automotive and medical industries. No financial terms were disclosed.

Paradigm Diagnostics attracts funding

Phoenix-based Paradigm Diagnostics, a precision medicine company focused on cancer diagnostics, has secured an undisclosed amount of funding. The investor was OSF Ventures.

Paradigm Diagnostics attracts funding

Phoenix-based Paradigm Diagnostics, a precision medicine company focused on cancer diagnostics, has secured an undisclosed amount of funding. The investor was OSF Ventures.

Bike shop operator Velofix rides off with funding

Vancouver, British Columbia-based Velofix, a bike shop operator, has secured an undisclosed amount of funding. The investor was MacKinnon, Bennett & Company.

Quell Therapeutics pulls in funding

UK-based Quell Therapeutics, a new cell therapy company, has secured 35 million pounds in funding. Syncona was the lead investor with participation from UCL Technology Fund.

Quell Therapeutics pulls in funding

UK-based Quell Therapeutics, a new cell therapy company, has secured 35 million pounds in funding. Syncona was the lead investor with participation from UCL Technology Fund.